Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Velesco Pharma Awarded Subcontract for Blood Disorder Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Velesco Pharma Awarded Subcontract for Blood Disorder Drug

The development, manufacturing, and testing of the drug will help to treat Beta-Thalassemia

By: Betsy Louda

, Contract Pharma

Velesco Pharmaceutical Services, Inc. has been awarded a $350,000 subcontract for the development, manufacturing, and testing of the stability of an investigational drug. The drug is intended to treat Beta-Thalassemia, a blood disorder that reduces the production of proteins that carry oxygen to cells throughout the body.

 

The subcontract is fully funded by the National Center for Advancing Translational Sciences (NCATS) through its Therapeutics for Rare and Neglected Diseases (TRND) program.

 

TRND staff select qualified contract research organizations to provide services supporting certain drug development projects. The goal is to accelerate translation of promising therapeutics for treating rare and neglected diseases.

 

Beta-Thalassemia continues to be a major public health problem in many parts of the world. Through TRND, NCATS seeks to rapidly advance this potential new treatment option to the clinic.

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters